BioVie Says Last On-Treatment Visit Completed In Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID; Expects Topline Results Before End Of September 2026

Benzinga Newsdesk www.benzinga.com Positive 71.2%

Neg 0% Neu 0% Pos 71.2%

Comments

No comments yet. Be the first!